[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

IL155368A0 - Ep4 receptor selective agonists in the treatment of osteoporosis - Google Patents

Ep4 receptor selective agonists in the treatment of osteoporosis

Info

Publication number
IL155368A0
IL155368A0 IL15536801A IL15536801A IL155368A0 IL 155368 A0 IL155368 A0 IL 155368A0 IL 15536801 A IL15536801 A IL 15536801A IL 15536801 A IL15536801 A IL 15536801A IL 155368 A0 IL155368 A0 IL 155368A0
Authority
IL
Israel
Prior art keywords
osteoporosis
treatment
selective agonists
receptor selective
receptor
Prior art date
Application number
IL15536801A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of IL155368A0 publication Critical patent/IL155368A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/20—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL15536801A 2000-11-27 2001-11-05 Ep4 receptor selective agonists in the treatment of osteoporosis IL155368A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25327500P 2000-11-27 2000-11-27
PCT/IB2001/002073 WO2002042268A2 (en) 2000-11-27 2001-11-05 Ep4 receptor selective agonists in the treatment of osteoporosis

Publications (1)

Publication Number Publication Date
IL155368A0 true IL155368A0 (en) 2003-11-23

Family

ID=22959588

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15536801A IL155368A0 (en) 2000-11-27 2001-11-05 Ep4 receptor selective agonists in the treatment of osteoporosis

Country Status (41)

Country Link
US (3) US6552067B2 (de)
EP (1) EP1339678B1 (de)
JP (2) JP3984164B2 (de)
KR (1) KR20030053063A (de)
CN (1) CN1476429A (de)
AR (1) AR035074A1 (de)
AT (1) ATE374182T1 (de)
AU (1) AU2002210848A1 (de)
BG (1) BG107697A (de)
BR (1) BR0115687A (de)
CA (1) CA2429850C (de)
CY (1) CY1106976T1 (de)
CZ (1) CZ20031257A3 (de)
DE (1) DE60130675T2 (de)
DK (1) DK1339678T3 (de)
EA (1) EA200300379A1 (de)
EC (1) ECSP034623A (de)
EE (1) EE200300246A (de)
ES (1) ES2291361T3 (de)
GT (2) GT200100238A (de)
HN (1) HN2001000266A (de)
HU (1) HUP0400807A2 (de)
IL (1) IL155368A0 (de)
IS (1) IS6775A (de)
MA (1) MA26961A1 (de)
MX (1) MXPA03004623A (de)
NO (1) NO20032360L (de)
NZ (1) NZ525164A (de)
OA (1) OA12533A (de)
PA (1) PA8533901A1 (de)
PE (1) PE20020637A1 (de)
PL (1) PL362030A1 (de)
PT (1) PT1339678E (de)
SI (1) SI1339678T1 (de)
SK (1) SK5562003A3 (de)
SV (1) SV2003000746A (de)
TN (1) TNSN01166A1 (de)
TW (1) TW200424170A (de)
UY (1) UY27038A1 (de)
WO (1) WO2002042268A2 (de)
ZA (1) ZA200302803B (de)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE374182T1 (de) * 2000-11-27 2007-10-15 Pfizer Prod Inc Selektive agonisten des ep4 rezeptors für die behandlung von osteoporose
BR0211201A (pt) * 2001-07-16 2004-07-13 Hoffmann La Roche Composto, processo para a preparação desse composto, sua utilização, composição farmacêutica que compreende o mesmo e método para o tratamento de uma enfermidade em um mamìfero
AU2002328338C1 (en) * 2001-07-16 2009-01-08 Ono Pharmaceutical Co., Ltd 2 pyrrolidone derivatives as prostanoid agonists
NZ530885A (en) 2001-07-23 2007-09-28 Ono Pharmaceutical Co Remedies for diseases with bone mass loss having EP4 agonist as the active ingredient
US20040254230A1 (en) * 2001-12-03 2004-12-16 Ogidigben Miller J. Method for treating ocular hypertension
US7402605B2 (en) 2002-03-05 2008-07-22 Ono Pharmaceutical Co., Ltd. 8-azaprostaglandin derivative compounds and drugs containing the compounds as the active ingredient
AU2003209571A1 (en) * 2002-03-18 2003-09-29 Pfizer Products Inc. Use of selective ep4 receptor agonists for the treatment of liver failure, loss of patency of the ductus arteriosus, glaucoma or ocular hypertension
DE60307607T2 (de) * 2002-03-18 2007-08-09 Pfizer Products Inc., Groton Verwendung von selektiven ep4 rezeptor agonisten zur behandlung von krankheiten
US6573294B1 (en) 2002-05-14 2003-06-03 Allergan, Inc. 8-azaprostaglandin analogs as agents for lowering intraocular pressure
WO2003103604A2 (en) * 2002-06-01 2003-12-18 Applied Research Systems Ars Holding N.V Gamma lactams as prostaglandin agonists and use thereof
US20050239872A1 (en) 2002-06-06 2005-10-27 Xavier Billot 1,5-distributed pyrrolid-2-one derivatives for use as ep4 receptor agonists in the teatment of eye diseases such as glaucoma
US20060258726A1 (en) * 2002-06-06 2006-11-16 Xavier Billot 1,5-Disubstituted imidazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of eye and bone diseases
GB0219143D0 (en) * 2002-08-16 2002-09-25 Univ Leicester Modified tailed oligonucleotides
PT2465537T (pt) 2002-10-10 2016-08-03 Ono Pharmaceutical Co Microsferas compreendendo ono-1301
WO2004037813A1 (en) * 2002-10-25 2004-05-06 Merck Frosst Canada & Co. Pyrrolidin-2-on derivatives as ep4 receptor agonists
EP1581503A4 (de) 2002-11-08 2007-07-25 Merck & Co Inc Ophthalmische zusammensetzungen zur behandlung der okularen hypertonie
US7196082B2 (en) 2002-11-08 2007-03-27 Merck & Co. Inc. Ophthalmic compositions for treating ocular hypertension
US7053085B2 (en) 2003-03-26 2006-05-30 Merck & Co. Inc. EP4 receptor agonist, compositions and methods thereof
BRPI0406717A (pt) * 2003-01-10 2005-12-20 Hoffmann La Roche Composto, composição farmacêutica que compreende o mesmo, método de tratamento de uma enfermidade em um mamìfero, utilização do composto e processo para a sua produção
US7256211B1 (en) * 2003-01-21 2007-08-14 Ono Pharmaceutical Co., Ltd. 8-azaprostaglandin derivatives and medical use thereof
ATE394372T1 (de) 2003-03-03 2008-05-15 Serono Lab G-lactamderivate als prostaglandinagonisten
US6734206B1 (en) 2003-06-02 2004-05-11 Allergan, Inc. 3-oxa-8-azaprostaglandin analogs as agents for lowering intraocular pressure
US6734201B1 (en) 2003-06-02 2004-05-11 Allergan, Inc. 8-Azaprostaglandin carbonate and thiocarbonate analogs as therapeutic agents
AU2004261397A1 (en) 2003-07-18 2005-02-10 Laboratoires Serono Sa Hydrazide derivatives as prostaglandin receptors modulators
US7034051B2 (en) * 2003-08-28 2006-04-25 Adolor Corporation Fused bicyclic carboxamide derivatives and methods of their use
US7576122B2 (en) 2003-09-02 2009-08-18 Merck & Co. Inc. Ophthalmic compositions for treating ocular hypertension
CN102558231B (zh) 2003-09-04 2015-05-27 默沙东公司 用于治疗高眼压的眼用组合物
AU2004271978B2 (en) 2003-09-04 2009-02-05 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
WO2005027931A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an ep2 or ep4 selective agonist
EP1696893A1 (de) * 2003-12-17 2006-09-06 Pfizer Products Incorporated Kontinuierliche kombinationstherapie mit selektivem prostaglandin-ep4, rezeptoragonisten und einem östrogen zur behandlung von erkrankungen mit geringer knochenmasse
US7169807B2 (en) * 2004-04-09 2007-01-30 Allergan, Inc. 10-Hydroxy-11-dihydroprostaglandin analogs as selective EP4 agonists
JP2008507521A (ja) 2004-07-20 2008-03-13 メルク　エンド　カムパニー　インコーポレーテッド 高眼圧症を治療するための眼科用組成物
US7858650B2 (en) 2004-10-22 2010-12-28 Ono Pharmaceutical Co., Ltd. Medicinal composition for inhalation
BRPI0518242A2 (pt) * 2004-10-26 2008-11-11 Allergan Inc mÉtodos terapÊuticos e de liberaÇço de agonistas de prostaglandina ep4
US7994195B2 (en) * 2004-11-04 2011-08-09 Allergan, Inc. Therapeutic substituted piperidone compounds
WO2006052893A2 (en) 2004-11-08 2006-05-18 Allergan, Inc. Substituted pyrrolidone compounds as ep4 agonists
US7101906B2 (en) * 2004-11-16 2006-09-05 Allergan, Inc. 2,3,4-substituted cyclopentanones as therapeutic agents
US7183324B2 (en) 2004-11-23 2007-02-27 Allergan, Inc. 2,3,4-substituted cyclopentanones as therapeutic agents
WO2006080323A1 (ja) * 2005-01-27 2006-08-03 Asahi Kasei Pharma Corporation ヘテロ６員環化合物及びその用途
US7531533B2 (en) 2005-01-27 2009-05-12 Asahi Kasei Pharma Corporation 6-Membered heterocyclic compound and use thereof
BRPI0611257A2 (pt) * 2005-05-06 2010-08-24 Allergan Inc beta-lactamas substituÍdas e uso em medicina do mesmo
US7772392B2 (en) 2005-05-06 2010-08-10 Allergan, Inc. Therapeutic substituted β-lactams
US7893107B2 (en) 2005-11-30 2011-02-22 Allergan, Inc. Therapeutic methods using prostaglandin EP4 agonist components
KR100598678B1 (ko) * 2006-02-15 2006-07-19 (주)아이앤씨 수직형 대형 폐기물 파쇄기
US20070232660A1 (en) * 2006-04-04 2007-10-04 Allergan, Inc. Therapeutic and delivery methods of prostaglandin ep4 agonists
WO2008073748A1 (en) 2006-12-08 2008-06-19 University Of Rochester Expansion of hematopoietic stem cells
BRPI0721067A2 (pt) 2006-12-18 2014-02-25 Allergan Inc Métodos e composições para tratar distúrbios gastrointestinais.
BRPI0811306A2 (pt) 2007-05-08 2015-01-27 Nat Univ Corp Hamamatsu Ativador de célula t citotóxica compreendendo agonista ep4
SI2155733T1 (sl) * 2007-05-23 2012-12-31 Allergan, Inc Ciklični laktami za zdravljenje glavkoma ali zvišanega očesnega tlaka
US8063033B2 (en) * 2008-01-18 2011-11-22 Allergan, Inc. Therapeutic beta-lactams
US8202855B2 (en) 2008-03-04 2012-06-19 Allergan, Inc Substituted beta-lactams
US7705001B2 (en) * 2008-03-18 2010-04-27 Allergan, Inc Therapeutic substituted gamma lactams
WO2010019796A1 (en) * 2008-08-14 2010-02-18 Chemietek, Llc Heterocyclic amide derivatives as ep4 receptor antagonists
WO2010116270A1 (en) 2009-04-10 2010-10-14 Pfizer Inc. Ep2/4 agonists
WO2011047048A1 (en) 2009-10-14 2011-04-21 Gemmus Pharma, Inc. Combination therapy treatment for viral infections
CN102917703B (zh) * 2010-03-08 2015-08-19 科研制药株式会社 新型ep4激动剂
CA2738045C (en) 2010-05-28 2019-02-19 Simon Fraser University Conjugate compounds, methods of making same, and uses thereof
EP2397141A1 (de) * 2010-06-16 2011-12-21 LEK Pharmaceuticals d.d. Verfahren zur Synthese von Beta-Aminosäuren und Derivaten daraus
US8697057B2 (en) 2010-08-19 2014-04-15 Allergan, Inc. Compositions and soft tissue replacement methods
AU2012217630A1 (en) 2011-02-17 2013-09-05 Allergan, Inc. Compositions and improved soft tissue replacement methods
WO2013105997A2 (en) 2011-02-23 2013-07-18 Allergan, Inc. Compositions and improved soft tissue replacement methods
WO2013123274A1 (en) 2012-02-16 2013-08-22 Allergan, Inc. Compositions and improved soft tissue replacement methods
WO2013123275A1 (en) 2012-02-16 2013-08-22 Allergan, Inc. Compositions and improved soft tissue replacement methods
EP2814510A1 (de) 2012-02-16 2014-12-24 Allergan, Inc. Zusammensetzungen und verbesserte verfahren für den ersatz von weichgewebe
EP2814482A1 (de) 2012-02-16 2014-12-24 Allergan, Inc. Zusammensetzungen und verbesserte verfahren für den ersatz von weichgewebe
ES2610428T3 (es) 2012-07-19 2017-04-27 Cayman Chemical Company, Incorporated Compuestos de difluorolactama como agonistas selectivos del receptor EP4 para su uso en el tratamiento de enfermedades y afecciones mediadas por EP4
EP2913047B1 (de) 2012-10-29 2019-05-08 Cardio Incorporated Spezifisches therapeutikum für pulmonale erkrankungen
CN105143217A (zh) 2013-03-15 2015-12-09 开曼化学股份有限公司 作为ep4受体选择性激动剂的内酰胺化合物用于治疗ep4介导的疾病和病症
JP6368351B2 (ja) 2013-03-15 2018-08-01 ケイマン ケミカル カンパニー， インコーポレーテッド ジフルオロラクタムアナログを合成する方法
WO2014144610A1 (en) 2013-03-15 2014-09-18 Cayman Chemical Company, Inc. Lactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated diseases and conditions
CN105392505A (zh) * 2013-07-19 2016-03-09 开曼化学股份有限公司 用于促进骨生长的方法、系统和组合物
US20160184387A1 (en) 2013-08-09 2016-06-30 Dominique Charmot Compounds and methods for inhibiting phosphate transport
WO2015056504A1 (ja) 2013-10-15 2015-04-23 小野薬品工業株式会社 薬剤溶出性ステントグラフト
US9650414B1 (en) 2014-05-30 2017-05-16 Simon Fraser University Dual-action EP4 agonist—bisphosphonate conjugates and uses thereof
TR201905436T4 (tr) 2014-06-06 2019-05-21 Allergan Inc Terapötik bileşikler olarak yeni ep4 agonistleri.
US9540357B1 (en) 2014-07-31 2017-01-10 Allergan, Inc. 15-aryl prostaglandins as EP4 agonists, and methods of use thereof
WO2016199111A1 (en) 2015-06-12 2016-12-15 Simon Fraser University Amide-linked ep4 agonist-bisphosphonate compounds and uses thereof
CN107011377B (zh) * 2017-05-03 2019-02-26 南通书创药业科技有限公司 一种β-羰基磷酸酯的制备方法
CN111511736B (zh) 2017-12-25 2023-03-24 旭化成制药株式会社 含氮6元环化合物
JP2022533251A (ja) 2019-05-21 2022-07-21 アルデリックス， インコーポレイテッド 患者において血清リン酸塩を低下させるための組み合わせ

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1158163A (en) 1966-06-15 1969-07-16 Berk Ltd Improvements in or relating to Polymer Compositions
ZA72645B (en) * 1971-03-05 1972-11-29 Upjohn Co Prostaglandin analogs
DE2346706A1 (de) * 1973-09-17 1975-04-03 Hoechst Ag Neue, nicht natuerlich vorkommende analoga von prostansaeuren und verfahren zu ihrer herstellung
US3975399A (en) 1974-08-06 1976-08-17 E. I. Du Pont De Nemours And Company 1,5-Disubstituted-2-pyrrolidinones, -3-pyrrolin-2-ones, and -4-pyrrolin-2-ones
US4113873A (en) 1975-04-26 1978-09-12 Tanabe Seiyaku Co. Ltd. 8-azaprostanoic acid derivatives
NL7604330A (nl) 1975-04-28 1976-11-01 Syntex Inc Werkwijze voor de bereiding van 8-azaprostaan- zuurderivaten.
DE2528664A1 (de) 1975-06-27 1977-01-13 Hoechst Ag Pyrrolidone und verfahren zu ihrer herstellung
IL49325A (en) 1976-03-31 1979-11-30 Labaz 8-aza-11-deoxy-pge1 derivatives,their preparation and pharmaceutical compositions containing them
DE2619638A1 (de) 1976-05-04 1977-11-17 Hoechst Ag Pyrrolidone und verfahren zu ihrer herstellung
CA1077948A (en) * 1976-08-06 1980-05-20 Albin J. Nelson 1,-5 disubstituted-2-pyrrolidones and processes for their production
US4177346A (en) * 1976-08-06 1979-12-04 Pfizer Inc. 1,5-Disubstituted-2-pyrrolidones
US4320136A (en) * 1980-08-11 1982-03-16 E. I. Du Pont De Nemours And Company 8-Aza-16,16-difluoroprostanoids
US4456613A (en) 1982-12-27 1984-06-26 E. I. Du Pont De Nemours And Company 6-Keto- and 6-hydroxy-8-azaprostanoids and anti-ulcer use thereof
TW288010B (de) 1992-03-05 1996-10-11 Pfizer
SE9302334D0 (sv) 1993-07-06 1993-07-06 Ab Astra New compounds
ZA944647B (en) 1993-07-06 1995-01-06 Astra Ab Novel (1-phenyl-1-heterocyclyl)methanol and (1-phenyl-1-heterocyclcl)methylamine derivatives
US5955481A (en) 1994-03-28 1999-09-21 Nissan Chemical Industries, Ltd. Pyridine type thiazolidines
TW420669B (en) 1994-03-28 2001-02-01 Nissan Chemical Ind Ltd Pyridine type thiazolidines
US5703108A (en) * 1996-02-28 1997-12-30 Pfizer Inc. Bone deposition by certain prostaglandin agonists
AU6427599A (en) * 1998-10-15 2000-05-01 Merck & Co., Inc. Methods for stimulating bone formation
JP2002527393A (ja) 1998-10-15 2002-08-27 メルク エンド カムパニー インコーポレーテッド 骨吸収阻害方法
WO2001046140A1 (en) * 1999-12-22 2001-06-28 Pfizer Products Inc. Ep4 receptor selective agonists in the treatment of osteoporosis
EP1132086B1 (de) * 2000-01-31 2006-05-31 Pfizer Products Inc. Verwendung von Aktivatoren des Prostaglandinrezeptores 4 zur Behandlung von akuter oder chronischer Niereninsuffizienz
US20010056060A1 (en) * 2000-02-07 2001-12-27 Cameron Kimberly O. Treatment of osteoporsis with EP2/EP4 receptor selective agonists
ATE374182T1 (de) * 2000-11-27 2007-10-15 Pfizer Prod Inc Selektive agonisten des ep4 rezeptors für die behandlung von osteoporose
US6573294B1 (en) * 2002-05-14 2003-06-03 Allergan, Inc. 8-azaprostaglandin analogs as agents for lowering intraocular pressure

Also Published As

Publication number Publication date
IS6775A (is) 2003-04-10
SI1339678T1 (sl) 2007-12-31
JP2007197467A (ja) 2007-08-09
BG107697A (en) 2004-01-30
NO20032360L (no) 2003-07-23
BR0115687A (pt) 2003-09-09
CZ20031257A3 (cs) 2004-04-14
CY1106976T1 (el) 2012-09-26
CA2429850A1 (en) 2002-05-30
PL362030A1 (en) 2004-10-18
TNSN01166A1 (fr) 2005-11-10
US7192979B2 (en) 2007-03-20
DE60130675T2 (de) 2008-01-24
DK1339678T3 (da) 2008-02-04
SK5562003A3 (en) 2004-08-03
ES2291361T3 (es) 2008-03-01
EA200300379A1 (ru) 2003-08-28
MA26961A1 (fr) 2004-12-20
ATE374182T1 (de) 2007-10-15
PE20020637A1 (es) 2002-07-18
MXPA03004623A (es) 2003-09-05
EP1339678B1 (de) 2007-09-26
JP3984164B2 (ja) 2007-10-03
HN2001000266A (es) 2002-01-30
PT1339678E (pt) 2007-11-30
EP1339678A2 (de) 2003-09-03
US20030149086A1 (en) 2003-08-07
DE60130675D1 (de) 2007-11-08
NZ525164A (en) 2005-04-29
TW200424170A (en) 2004-11-16
AU2002210848A1 (en) 2002-06-03
ZA200302803B (en) 2004-04-13
PA8533901A1 (es) 2002-11-28
NO20032360D0 (no) 2003-05-26
US6747054B2 (en) 2004-06-08
SV2003000746A (es) 2003-01-13
HUP0400807A2 (hu) 2004-07-28
JP2004521869A (ja) 2004-07-22
CA2429850C (en) 2008-12-30
US20040259921A1 (en) 2004-12-23
EE200300246A (et) 2003-10-15
AR035074A1 (es) 2004-04-14
KR20030053063A (ko) 2003-06-27
GT200100238AA (es) 2004-05-12
WO2002042268A3 (en) 2002-07-25
OA12533A (en) 2006-06-05
GT200100238A (es) 2002-06-26
US20020065308A1 (en) 2002-05-30
US6552067B2 (en) 2003-04-22
WO2002042268A2 (en) 2002-05-30
ECSP034623A (es) 2003-07-25
CN1476429A (zh) 2004-02-18
UY27038A1 (es) 2002-07-31

Similar Documents

Publication Publication Date Title
IL155368A0 (en) Ep4 receptor selective agonists in the treatment of osteoporosis
IL140325A0 (en) Ep4 receptor selective agonists in the treatment of osteoporosis
GB0018741D0 (en) Assay apparatus
GB0003397D0 (en) Therapeutic agents
IL152700A0 (en) Substituted 1-aminoalkyl-lactams and their use as muscarinc receptor antagonists
EP1121939A3 (de) Behandlung von Osteoporosis mit selektive EP2/EP4 Receptor-Agonisten
GB2369327B (en) Water-monitoring apparatus with anchor
GB0000564D0 (en) Therapeutic agents
TW489655U (en) Waist swinging device
AU9275001A (en) Notch receptor agonists and uses
GB0030067D0 (en) Therapeutic agent
AU2002336782A8 (en) Penis vibrator
TW479626U (en) Treatment device for junk
GB2359053B (en) Anchoring device
TW458308U (en) Carrying apparatus
GB0024319D0 (en) Mixing device
PL111452U1 (en) Drilling anchoring apparatus
GB0019042D0 (en) Scarifying apparatus
GB0023647D0 (en) Monitor mixer
AU148862S (en) Massage apparatus
GB0003992D0 (en) Mixing apparatus
GB0000296D0 (en) Mixing apparatus
GB0027729D0 (en) Mixing apparatus
GB0002012D0 (en) Anchoring device
GB0024165D0 (en) Anchoring device